Dr Ashwin Nandakumar is Founder & CEO of Granza Bio, currently being accelerated by Y Combinator, having previously Co-founded OncoAssign, an AI-powered biomarker-driven platform to enable oncologists to identify the most suitable treatment for a cancer patient, to prevent relapse and toxicity. OncoAssign's diagnostics are developed using biomarkers discovered and validated on thousands of clinical patient samples and can accurately predict the most beneficial treatment for a cancer patient.
Ashwin is also a postdoctoral scientist at the Nuffield Department of Surgical Sciences, University of Oxford, investigating the effects of IGF-1 on prostate cancer and at the Institute of Cancer Research. He holds a Doctor of Philosophy (DPhil) degree in Oncology from the University of Oxford and a Bachelor's degree in Biomedical Science from Kingston University, London. Ashwin was shortlisted as one of the top 10 Early-Career Entrepreneurs in the UK in 2022 by Cancer Research UK.